Skip to main content
An official website of the United States government

Success Stories

The National Cancer Institute’s Technology Transfer Center (TTC) facilitates partnerships between the NIH research laboratories and external partners. With a specialized team, TTC guides the interactions of our partners from the point of discovery, to patenting, through invention development to licensing.

We play a key role in helping to accelerate  development of cutting-edge research by connecting our partners to NIH’s world-class facilities, resources, and discoveries. Some of our partnerships have resulted in the commercialization of therapeutics, vaccines, diagnostics, medical devices and research tools that benefit patients worldwide. TTC is proud to share a few examples of our successful partnerships.

  • Dinutuximab (Unituxin™) - A Success Story

    Learn about the 2015 FDA approval of Unituxin™ as part of first-line therapy for pediatric patients with high-risk neuroblastoma, a rare cancer that most often occurs in young children, and the role that the NCI Technology Transfer Center played to facilitate this outcome.

  • Halaven - A Success Story

    Learn more about the technology transfer story behind the development of the drug, Halaven®.

  • Velcade - A Success Story

    The discovery of Velcade® for the treatment of multiple myeloma (MM) originated from a collaboration with ProScript Inc. and NCI scientists in the Developmental Therapeutics Program.

  • Micatu Tissue Arrayer - A Success Story

    An NCI researcher recognized a critical need to create a low-cost, easy-to-use tissue microarrayer (TMA), an instrument used by researchers and pathologists to accurately examine tissue samples from patients.

  • Gardasil and Cervarix - A Success Story

    Learn the discovery to commercialization story for Gardasil, a vaccine to prevent human papillomavirus (HPV) infection, the primary cause of cervical cancer.

  • Taxol - A Success Story

    In the 1980s, the drug Taxol was fully developed under an agreement between NCI and Bristol-Myers Squibb.